Universe Pharmaceuticals (NASDAQ:UPC) experienced a remarkable surge in premarket trading on Monday, with shares climbing more than 130% following the completion of its acquisition of Best Praise International. The stock was trading at $7.39 as of 6:00 a.m. EDT, representing a 133.9% jump from Friday's closing price of $3.16.
The dramatic move came after the company revealed in a July 31 filing that it had issued 4.377 million new Class A shares as consideration for the acquisition. This issuance increased the total number of Class A shares outstanding from an implied 631,761 to 5.008 million, marking a 693% expansion in the share count. The newly issued shares represent approximately 87.4% of the post-transaction Class A shares.
Based on the premarket price, the consideration shares were valued at roughly $32.3 million, more than triple the $10.751 million contractual deal value. This discrepancy highlights the significant market revaluation of the transaction following the announcement.
The acquisition of Best Praise International grants Universe Pharmaceuticals full ownership of five patents in China, covering age-related illnesses, cognitive disorders, and drug delivery technologies. CEO Gang Lai had previously indicated in June that the deal could "broaden its product pipeline."
Financial Performance and Market Reaction
Universe Pharmaceuticals also reported its half-year financial results for the period ending March 31, 2026. Revenue declined 1.3% year-over-year to $9.04 million, while gross margin improved by 2.4 percentage points to 37.0%. The company narrowed its net loss by 52.7% to $1.55 million, though operating cash flow turned negative at -$4.30 million compared to positive $2.56 million in the prior year period.
The margin improvement came despite a 26.2% drop in traditional Chinese medicine volumes and a 19.2% decline in third-party product volumes. However, the average selling price for third-party products jumped 81.5%, helping to offset the volume decline.
As of March 31, the company held $27.6 million in cash and $1.49 million in short-term investments, with bank loans of approximately $9.55 million. The stock had been under pressure recently, falling 47.3% over the past month and 8.4% for the week before Friday's close. The after-hours rally reversed that trend, at least temporarily.
Investor Considerations
The post-transaction share structure includes 5.008 million Class A shares and 16,077 Class B shares. The newly issued shares are restricted but include resale-registration rights, which could increase supply in the future. Investors should note that the premarket rally may face volatility once regular trading begins at 9:30 a.m. EDT, and the validity and commercial potential of the acquired patents remain uncertain.
With the current share price, the company's implied equity value stands at approximately $40.8 million, about 2.28 times projected fiscal 2025 revenue of $17.86 million. The balance sheet provides some downside protection, with cash and liquid assets totaling $29.05 million as of March 31, though the company is still consuming cash in operations.
